文献速递肿瘤 PET/CT

新诊断乳腺癌淋巴结分期:CT、MRI与[18F]-FDG PET/MRI对比

Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-09-03

患者基线分析显示PET/MRI显著优于MRI和CT(p<0.0001),病灶分析亦显示PET/MRI优于MRI和CT(p<0.0001),MRI仅腋窝I级优于CT(p=0.0291)。PET/MRI敏感性最高,CT特异性最高。

要点

  • PET/MRI在患者基线和病灶分析中均显著优于MRI和CT检出淋巴结转移。
  • PET/MRI在各淋巴结站(腋窝I-III、锁骨上、内乳)均显著优于MRI和CT。
  • CT敏感性最低但特异性最高;MRI仅在腋窝I级优于CT(p=0.0291)。

核心结论

  • 在患者基线和病灶分析中,[18F]-FDG PET/MRI检测淋巴结受累均优于CT或MRI。
  • PET/MRI在所有淋巴结站检测淋巴结转移均优于CT或MRI。
  • 所有测试成像方式中,PET/MRI敏感性最高,CT敏感性最低但特异性最高。

研究设计与样本

  • 患者接受对比增强胸/腹/盆腔CT和全身[18F]-FDG PET/MRI检查。
  • 胸部数据集分别评估淋巴结数量、淋巴结站(腋窝I-III级、锁骨上、内乳链)和病灶性质(良恶性)。
  • 组织病理学作为患者基线分析的参考标准。
  • 患者基线和病灶分析采用McNemar检验比较。

主要发现

  • 患者基线分析中,PET/MRI正确检测到的淋巴结阳性患者显著多于MRI(p<0.0001)和CT(p<0.0001)。
  • CT与MRI之间无统计学显著差异。
  • PET/MRI在75例患者(41.2%)中检测到193个病灶,MRI在56例患者(30.8%)中检测到123个病灶,CT在50例患者中检测到104个病灶。
  • 病灶分析差异有统计学意义:PET/MRI vs MRI(p<0.0001)、PET/MRI vs CT(p<0.0001)、MRI vs CT(p=0.015)。
  • 亚组分析显示,PET/MRI在每个淋巴结站(腋窝I-III级、锁骨上、内乳链)检测到的淋巴结转移均显著多于MRI和CT;MRI仅在腋窝I级优于CT(p=0.0291)。

关键数值与推荐

  • PET/MRI在75例患者(41.2%)中检出193个病灶;MRI在56例患者(30.8%)中检出123个病灶;CT在50例患者中检出104个病灶。
  • 患者基线分析:PET/MRI vs MRI p<0.0001,PET/MRI vs CT p<0.0001。
  • 病灶分析:PET/MRI vs MRI p<0.0001,PET/MRI vs CT p<0.0001,MRI vs CT p=0.015。
  • 腋窝I级:MRI vs CT p=0.0291。

临床怎么用

  • 对新诊断乳腺癌患者,[18F]-FDG PET/MRI在淋巴结分期中检出率高于CT或MRI。
  • PET/MRI在各淋巴结站(腋窝I-III、锁骨上、内乳)检测转移均优于CT和MRI。
  • CT敏感性最低但特异性最高,临床选择成像方式时可结合对敏感性和特异性的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare CT, MRI, and [18F]-fluorodeoxyglucose positron emission tomography ([18F]-FDG PET/MRI) for nodal status, regarding quantity and location of metastatic locoregional lymph nodes in patients with newly diagnosed breast cancer. MATERIALS AND METHODS: One hundred eighty-two patients (mean age 52.7 ± 11.9 years) were included in this prospective double-center study. Patients underwent dedicated contrast-enhanced chest/abdomen/pelvis computed tomography (CT) and whole-body ([18F]-FDG PET/) magnet resonance imaging (MRI). Thoracal datasets were evaluated separately regarding quantity, lymph node station (axillary levels I-III, supraclavicular, internal mammary chain), and lesion character (benign vs. malign). Histopathology served as reference standard for patient-based analysis. Patient-based and lesion-based analyses were compared by a McNemar test. Sensitivity, specificity, positive and negative predictive values, and accuracy were assessed for all three imaging modalities. RESULTS: On a patient-based analysis, PET/MRI correctly detected significantly more nodal positive patients than MRI (p < 0.0001) and CT (p < 0.0001). No statistically significant difference was seen between CT and MRI. PET/MRI detected 193 lesions in 75 patients (41.2%), while MRI detected 123 lesions in 56 patients (30.8%) and CT detected 104 lesions in 50 patients, respectively. Differences were statistically significant on a lesion-based analysis (PET/MRI vs. MRI, p < 0.0001; PET/MRI vs. CT, p < 0.0001; MRI vs. CT, p = 0.015). Subgroup analysis for different lymph node stations showed that PET/MRI detected significantly more lymph node metastases than MRI and CT in each location (axillary levels I-III, supraclavicular, mammary internal chain). MRI was superior to CT only in axillary level I (p = 0.0291). CONCLUSION: [18F]-FDG PET/MRI outperforms CT or MRI in detecting nodal involvement on a patient-based analysis and on a lesion-based analysis. Furthermore, PET/MRI was superior to CT or MRI in detecting lymph node metastases in all lymph node stations. Of all the tested imaging modalities, PET/MRI showed the highest sensitivity, whereas CT showed the lowest sensitivity, but was most specific.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Morawitz J, Bruckmann NM, Dietzel F, et al. Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34476552. doi:10.1007/s00259-021-05502-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。